Vycor Medical earnings release, May 15, 2026

Vycor Medical Inc (VYCO) · Form 8-K, Item 2.02 · Filed · SEC filing

Exhibit

99.1

Vycor

Medical Releases Financial Results for the Three Months Ended March 31, 2026

BOCA

RATON, FL (May 15, 2026) – Vycor Medical, Inc. (“Vycor”) (OTCQB—VYCO), today announced financial results for the three months ended March 31, 2026.

The

Company operates through two business units: Vycor Medical, which produces the ViewSite™ Brain Access System (VBAS) for neurosurgeons; and NovaVision®, a business in development which offers therapy programs to help patients recover from visual disorders after stroke or other brain injury.

Company

Highlights

Financial

Results

For the three months ended March 31, 2026, the Company reported revenue of $458,540, an increase of $22,162 (or 5%) over the 2025 period.

The Vycor Medical division (VBAS) generated revenue of $440,441, an increase of $21,921 (or 5%) over the 2025 period. Most of the increase came from international growth, a key company strategy. Gross profit for 2025 was $359,040, a 5% increase over 2024, generating a margin of 82% for both periods. The NovaVision division, which remains in development, generated revenues of $18,099 for the three months ended

March 31, 2026, a slight over the 2025 period, and gross margin of 89%, compared to 94%.

For the three months ended March 31, 2026 the Company reported non-GAAP Cash Operating Expenses of $315,365 compared to $338,146 in the 2025 period, and non-GAAP Operating Profit of $59,788 compared to $20,388 in the 2025 period, an increase of $39,400.

Reconciliation of Non-GAAP Information

Non-GAAP

Reconciliation

Management uses certain non-GAAP financial measures (including non-GAAP operating expenses and non-GAAP net loss and loss per share), which exclude non-cash depreciation of purchased assets and non-cash stock-based compensation. Management does not consider these costs in evaluating the continuing operations of the Company. Therefore, management calculates the non-GAAP financial measures provided in this earnings release excluding these costs and uses these non-GAAP financial measures to enable it to analyze further, and more consistently, the period-to-period financial performance of its core business operations. Management believes that providing investors with these non-GAAP measures gives them additional important information to enable them to assess, in the same way management assesses, the Company’s current and future continuing operations. There are limitations in using these non-GAAP financial measures because they are not prepared in accordance with GAAP and may be different from non-GAAP financial measures used by other companies. These non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial measures. Investors and potential investors should consider non-GAAP financial measures only in conjunction with the Company’s consolidated financial statements prepared in accordance with

GAAP. Set forth below are reconciliations of the non-GAAP financial measures to the comparable GAAP financial measures.

On a GAAP basis for three months ended March 31, 2026 the Company reported Operating Expenses of $329,345, an operating profit of $45,808, a net loss of $(142,077) or $(0.0 per share.

Vycor’s

GAAP operating costs for three months ended March 31, 2026 include non-cash depreciation of purchased assets ($13,980). The Company is providing additional non-GAAP financial measures that exclude these charges and expenses, and reconciliation of GAAP to non-GAAP results is provided in the tables included in this release.

On a non-GAAP basis, taking into account these adjustments, operating expenses for the three months ended March 31, 2026 were $315,365, non-GAAP operating profit was $59,788, and non-GAAP net loss was $(128,097) or $(0.00) per share.

VYCOR

MEDICAL, INC.

Consolidated

Statements of Comprehensive Loss

(unaudited)

VYCOR

MEDICAL, INC.

Non-GAAP

Reconciliation of Operating Loss and Net Loss

(unaudited)

(1)

Non-Cash depreciation of purchased assets.

These are non-cash charges related to assets which can be impacted by the timing and magnitude of acquisitions. We consider our operating results without these charges when evaluating our ongoing costs and performance and therefore exclude such charges when presenting non-GAAP financial measures.

(2)

Non-Cash Stock-based compensation expense consists of expense relating to stock-based compensation issued to employees, outside directors and non-employees including stock options, restricted common stock, and warrants. Because of varying available valuation methodologies, subjective assumptions and the fact that these amounts vary in size and timing, we believe that the exclusion of stock-based compensation expense allows for a more accurate comparison of our financial results to previous periods. In addition, we believe it is useful to investors to understand the specific impact of stock-based compensation expenses on our operating results.

About

Vycor Medical, Inc.

With corporate headquarters in Boca Raton, FL, Vycor Medical, Inc. (“Vycor”) is a publicly traded company (OTCQB: VYCO) dedicated to providing the medical community with innovative and superior surgical and therapeutic solutions and has a growing portfolio of FDA cleared or registered medical solutions that are changing and improving lives every day. The Company operates two business units: Vycor

Medical and NovaVision, both of which adopt a minimally or non-invasive approach.

Vycor

Medical’s FDA-cleared ViewSite™ Brain Access System (VBAS) a minimally invasive neurosurgical device designed to improve access to brain lesions while reducing tissue damage and enhancing patient outcomes. The VBAS system has been approved and used in over... (truncated)ending patents and has been validated through over 50 peer-reviewed studies. These studies demonstrate that use of VBAS results in: less brain tissue damage; less invasive procedure; improved access and better visibility; and reduced operating and recovery time. For an overview of Vycor Medical’s

VBAS see

VBAS Video.

NovaVision provides a suite of clinically supported vision rehabilitation therapies aimed at helping patients recover from visual impairments caused by stroke or other brain injury. The Visual Restoration Therapy (VRT) is the only commercialized FDA-cleared therapy for vision rehabilitation following neurological brain damage, making it a unique and important option for patients seeking to regain lost visual capabilities.

The complementary NeuroEyeCoach program, clinically supported by a 296-patient study (the largest to date in the neuro visual space), enables dramatic improvements in patients’ ability to detect objects in the visual field by training them to make better eye movements with improvement in over 80% of patients. The NovaVision therapies, while showing a positive impact on these patients’ lives, still require significant development to allow them to successfully address their market potential. For an overview of NovaVision see

NovaVision

Video.

For the latest information on the company, including media and other coverage, and to learn more, please go online at www.vycormedical.com, www.vycorvbas.com or www.novavision.com.

Safe

Harbor Statement

Financial statements

Income Statement

Three Months Ended March 31,

Three Months Ended March 31, – 2026Three Months Ended March 31, – 2025
RevenueVycor Medical440,441418,520
RevenueNovaVision18,09917,858
Revenue458,540436,378
Gross ProfitVycor Medical359,040341,798
Gross ProfitNovaVision16,11316,736
Gross Profit375,153358,534

Income Statement

For the three months ended March, 31 — (unaudited)

For the three months ended March, 31 – 2026For the three months ended March, 31 – 2025
Revenue458,540436,378
Cost of Goods Sold83,38777,844
Gross Profit375,153358,534
Operating Expenses:Research and development5,762
Operating Expenses:Depreciation and amortization13,98014,880
Operating Expenses:Selling, general and administrative315,365350,698
Operating Expenses:Total Operating Expenses329,345371,340
Operating Expenses:Operating income (loss)45,808-12,806
Other (Expense) IncomeInterest expense: Related Party-12,570-12,570
Other (Expense) IncomeInterest expense: Other-13,139-13,139
Other (Expense) Income(Loss) gain on foreign currency exchange-41
Other (Expense) IncomeTotal Other (Expense)-25,713-25,708
Other (Expense) IncomeIncome (Loss) Before Provision for Income Taxes20,095-38,514
Other (Expense) IncomeNet Income (Loss) from continuing operations20,095-38,514
Other (Expense) IncomeIncome (Loss) from discontinued operations, net of tax13-49
Other (Expense) IncomeNet Income (Loss)20,108-38,563
Other (Expense) IncomePreferred stock dividends-162,185-162,185
Other (Expense) IncomeNet Loss Available to Common Stockholders-142,077-200,748
Other Comprehensive Income (Loss)Comprehensive Income (Loss)20,108-38,563
Income (Loss) Per Share - basic and dilutedLoss from continuing operations0-0.01
Income (Loss) Per Share - basic and dilutedIncome (Loss) from discontinued operations00
Income (Loss) Per Share - basic and dilutedLoss available to common stockholders0-0.01
Income (Loss) Per Share - basic and dilutedWeighted Average Number of Shares Outstanding – Basic and Diluted33,372,79633,372,796

Income Statement

For the three months ended — (unaudited)

For the three months ended – March 31, – 2025For the three months ended – March 31, – 2024
GAAP Operating Expenses329,345371,340
Non-cash depreciation of purchased assets (1)-13,980-14,880
Non-cash stock-based compensation (2)-18,314
Total Non-GAAP Operating Expense Adjustments-13,980-33,194
Non GAAP Cash Operating Expenses315,365338,146
GAAP Operating Profit (Loss)45,808-12,806
Non-GAAP Operating Expense Adjustments, as above13,98033,194
Non-GAAP Operating Profit59,78820,388
GAAP Net Loss available to common shareholders-142,077-200,748
Non-GAAP Operating Expense Adjustments, as above13,98033,194
Non-GAAP Net Loss available to common stockholders-128,097-167,554
Non-GAAP Loss Per Share basic and diluted0-0.01
Weighted Average Number of Shares Outstanding – Basic33,372,79633,372,796
Full release

Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “forecast”, “anticipate”,

“estimate”, “project”, “intend”, “expect”, “should”, “believe”, and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Vycor Medical’s actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Vycor Medical’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Vycor Medical herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Vycor Medical disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.

Vycor

Medical, Inc. Contacts:

951

Broken Sound Parkway, Suite 320

Boca

Raton, FL. 33487

(561)

558-2020 info@vycormedical.com

LinkedIn: https://www.linkedin.com/in/vycor-medical-inc/

Instagram: https://www.instagram.com/vycormedical/

Facebook: https://www.facebook.com/Vycor.Nova/

Twitter/X: https://x.com/vycormedical

YouTube: https://www.youtube.com/@vycormedical6049

##END##

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Vycor Medical earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.